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significance in either case. Bowel dysfunction in ACC is 
frequently attributed to treatment-related toxicity, however our 
data support the hypothesis that dysfunction is frequently 
multifactorial, including disease, comorbidity, and psychosocial 
factors in addition to treatment factors, and that adequate 
baseline assessment of function is essential prior to CRT. 
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Purpose: Chemoradiation (CRT) followed by surgery has become 
the standard of care for the treatment of localized esophageal 
carcinoma. The rationale for this study was to examine survival 
outcomes and Quality of Life (QOL) in esophageal carcinoma 
patients treated with tri-modality therapy in a community 
cancer centre. 
Methods and Materials: Patients identified between June 2010 
and November 2015 with a diagnosis of adenocarcinoma or 
squamous cell carcinoma of the esophagus, Stage T1-4N0-3 (AJCC 
7th Ed.) and undergoing tri-modality treatment were eligible for 
this prospective cohort study. QOL (EORTC QLQ C30) and toxicity 
data (CTCAE v3.0) were collected at baseline, and four weeks, 
six months, and yearly post-completion of CRT. 
Results: Sixty patients consented to participate. Data was 
collected prospectively on 40 patients from diagnosis. Data was 
collected retrospectively for 20 patients diagnosed between 
June 2010 to February 2013 when consented at time of follow 
up, then followed prospectively thereafter. Thirty-three were 
treated with neoadjuvant CRT with 45-50 Gy in 25 fractions with 
concurrent 5FU and Cisplatin and 27 patients with 41.4 Gy in 23 
fractions, with carboplatin and paclitaxel (CROSS protocol). 
Median age was 66 years (range: 40-78) with 90% males. Median 
follow up was 13 months (range 2.3-53). Baseline QOL data was 
collected in 38 patients in the prospective group. Pathological 
complete response (pCR) rates were 38% for those receiving CRT 
with cisplatin/5FU and 22% for those treated with the CROSS 
protocol. Two-year overall survival (OS) and disease-free survival 
(DFS) was 68% and 53%, respectively with a median survival of 28 
months. No significant differences were seen in DFS or OS 
between the two treatment regimens (p = 0.95), nor were 
improved outcomes associated with achieving a pCR (p = 0.17). 
Median time to recurrence was 16 months, with locoregional 
recurrence in 17%, distant in 12% and both in 5%. No association 
was found between baseline global QOL and OS (HR = 0.9, 95% 
CI: 0.6-1.4) or DFS (HR = 0.8, 95% CI: 0.3-2.4). Additional QOL 
data will be presented. 
Conclusions: Survival outcomes in our cohort are in line with 
those reported in the literature, although pCR rates in our CROSS 
protocol group were lower compared to the CROSS study, and 
with short follow up pCR was not significantly associated with 
better survival outcomes. 
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Purpose: Radiotherapy (RT) for Hodgkin lymphoma (HL) is 
associated with late cardiac toxicity (LCT) as a potential 
complication after treatment. Risk of LCT is known to increase 
with increasing mean heart dose, however, it is unknown 
whether evaluating dose to heart substructures, such as the 
coronary arteries, will provide additional information to predict 
LCT risk. This study evaluated whether estimating dose to 
coronary arteries (CA) provided additional explanatory 
information for LCT compared to estimating whole heart dose 
alone. 
Methods and Materials: LCT status of 599 patients receiving 
mediastinal RT for HL at a tertiary cancer centre between 1988-
2003 was determined from medical records and with linkage to 
a population-based hospitalization dataset. A random sample of 
125 of these patients was selected and biomechanical 
deformable image registration was used to reconstruct 3D heart 
volumes from 2D imaging using validated methods. Historical RT 
plans were reconstructed on the 3D CT data sets and the heart 
and coronary arteries were contoured to estimate dose-volume 
variables to these structures. Principal Component analysis (PCA) 
was used to compare the proportion of variation in LCT explained 
by dose-volume variables to the whole heart versus the heart 
plus CA. The contribution (loadings) of different parameters 
(Dmean, Dmax, Dmin, V5, V10, V20, V30) to LCT occurrence was 
also evaluated. 
Results: Forty-four cases of LCT were seen, 30 of which were 
ischemic; other LCT included valvular disease, arrhythmias, 
pericardial disease, and heart failure. Median follow up was 10.4 
years (range: 0.15 – 23.8). Median Dmean to the heart, right 
coronary, left anterior descending, and circumflex arteries were 
24.6 Gy, 29.8 Gy, 17.3 Gy, and 27.3 Gy, respectively. Both the 
PCA of the heart and the heart plus CA had first components that 
explained > 50% of the variance in LCT, and there was no 
substantial improvement in explanatory power by adding CA 
doses in addition to whole heart doses to the PCA. Within 
components, no single dose-volume parameter explained a large 
proportion of LCT (i.e. loading > 0.5): in both whole heart, and 
heart plus CA models, the mean heart dose contributed most to 
explaining LCT (loading = 0.41 and 0.25, respectively).  
Conclusions: Our results indicate that estimating dose to CA will 
not add significant explanatory power to predict LCT in HL 
survivors, compared with documenting dose to the whole heart 
only. LCT risk in this setting may be mostly predicted by age, 
sex, comorbidities, and mean heart dose. However, our study 
may be underpowered to detect a small contribution from dose 
to the CA that is distinct from whole heart dose. 
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Purpose:  The management of patients with distant metastasis 
has historically been systemic therapy (ST). However, that 
paradigm is shifting to individually personalized care. 
Stereotactic body radiotherapy (SBRT) enables non-invasive 
ablation of liver metastases and its use is increasing despite the 
lack of randomized evidence. We reviewed the outcomes of liver 
metastases treated with SBRT at our institution, and evaluated 
the impact of liver SBRT on the treatment algorithm of 
metastatic patients on ST. 
Materials and Methods:  The records of 112 patients with 149 
metastatic liver lesions treated with SBRT between 2011 and 
2015 were retrospectively reviewed. Indications for treatment 
were: oligometastasis (OM) where the objective was to eradicate 
all sites of disease (≤5 sites); oligoprogression (OP) where only 
progressing lesions were treated while other sites were stable, 
and dominant area of progression (DAP) where a growing or 
symptomatic site was treated even if most or all metastatic 
deposits were progressing. Lesions were treated with either a 3, 
5 or 6 fraction regimen delivered every other day. All patients 
were evaluable for response based on contrast-enhanced CT 
obtained at minimum of 4 months after completion of SBRT. 
Local control (LC), time to liver failure (TLF), time to change ST 
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strategy (TST), progression-free survival (PFS) and overall 
survival (OS) were calculated from the start of SBRT to the date 
of the event or last follow-up. Kaplan-Meier method was used. A 
univariate and multivariable Cox proportional hazard model was 
performed to determine predictors of outcomes. A two-tailed p-
value ≤ 0.05 was considered statistically significant. 
Results:  The median follow-up was 14.8 months. Median age was 
66.5 years. The most common primary sites were colorectal (52), 
breast (16), lung (12) and renal cell (6). Median BED10 was 
92.7Gy (59-102). All patients were able to complete prescribed 
therapy. None of the patients developed Grade 3+ toxicity. For 
the OM subgroup (90 lesions), actuarial LC at 1 year was 79.5% 
(71-89%). BED10 ≥ 80 Gy (HR: 2.15, 95%CI: 1.1-4.0, p=0.0175) 
predicted for higher LC. The median TLF was 20 months (11-44) 
for OM patients. At 1 year, the probability of no change in ST 
strategy was 64.7% (55-74). The median TST was 11.1 months 
(8.2-13.9) for the entire cohort. For the OM subgroup (60 
patients), the probability of no change in ST at 1 year was 82.1% 
(72-92) compared to the OP group (40.3%). The actuarial 1 year 
PFS was 42% (31-57%) for OM, and 11.8% (5-30%) for OP patients, 
respectively. Treatment indication predicted for higher PFS, OM 
vs. OP (HR: 2.16, 95% CI: 1.36-3.4, p-value 0.001). Median OS was 
25.2 months (16-41). Primary colorectal cancer (p=0.0456) and 
treatment indication predicted for OS on univariate, but only 
treatment indication remained significant on multivariate 
analysis (OM vs. OP HR: 2.48, 95 %CI: 1.34-4.58 p=0.0037). 
Conclusions:  Outcomes for liver metastases treated with SBRT 
are favorable. Liver SBRT may delay the need to start or change  
ST, and warrants further prospective evaluation. 
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Purpose: The optimal management for limited, non-resectable 
brain metastases is an evolving area in radiation oncology. 
Previous data from randomized trials showed no difference in 
overall survival between radiation treatment with SRS and SRS + 
WBRT. Therefore patient preference plays an important role in 
decision making. This study uses a patient-centred approach to 
elicit patient preferences and understand what factors patients 
consider important in deciding which treatment to pursue.  
Methods and Materials: Patients were eligible for the study if all 
the following criteria were met: maximum of four brain lesions, 
RPA class 1 or 2, and the physician believes either treatment is 
appropriate and maintains an equipoise when discussing 
treatment options. Patients were excluded if they had brain 
metastases that were previously treated. All enrolled patients 
were presented with a decision board instrument which 
describes the two treatments and summarizes the evidence from 
the major trials regarding disease control and toxicity profiles. 
The patients reviewed the information and were able to ask 
questions at the initial consultation. The patients then had the 
option to either take an active role or passive role in further 
decision making. If taking a passive role, this decision was left to 
the clinician. If taking an active role, they would make the 
decision about whether to receive SRS alone, or in combination 
with WBRT. All patients who took an active role in management 
completed a debriefing questionnaire to rank from 0-10 how 
important 10 factors were in making their decision.  
Results: Between two centres in Canada and USA, 23 patients 
who were eligible to receive radiosurgery for brain metastases 
were enrolled in the study. All enrolled patients preferred to 
take an active role in deciding their treatment. The majority of 
patients (21/23) chose to receive SRS alone and two of 23 
patients chose to receive SRS + WBRT. From the debriefing 
questionnaire, the highest ranked factors were quality of life 
(avg = 9.4, SD = 1.03), ability to maintain functional 
independence (avg = 9.3, SD = 0.83) and influence of treatment 
on survival (avg = 9.2, SD = 1.87). The least important factor was 
number of trips required to the cancer centre (avg = 5.0, SD = 
4.22) 
Conclusions: A patient-centred approach to decision making in 
brain metastases is feasible and the majority of patients will 
choose to take an active role in management if all the relevant 
information and evidence is presented in a clear, understandable 
manner. The results of this study show that the majority of 
patients prefer SRS alone in comparison to SRS + WBRT and rank 
quality of life, ability to maintain functional independence and 
influence of treatment on survival as highly important factors in 
making their decision. 
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Purpose:  Bolus is a tissue-equivalent material used in 
radiotherapy to increase the radiation dose delivered to the skin 
surface or to compensate for irregular tissue shape or missing 
tissue. Although using commercially available bolus material is 
an effective and widely used approach, significant shortcomings 
include an inability of standard bolus to perfectly conform to 
very irregular surfaces, creation of air gaps between the skin 
surface and bolus, availability of only limited uniform 
thicknesses and long setup times required to construct complex 
pieces of bolus material for difficult treatment areas. We aimed 
to address these shortcomings by using 3D printer technology in 
combination with an optical scanner to create precise and rigid 
boluses. 
Methods and Materials:  Detailed optical images of non-patient 
volunteers involved in this study were acquired using a 
consumer-grade optical scanner (3D Systems, Sense). A three-
dimensional model of each volunteer was exported to a mesh 
editing software (Autodesk, MeshMixer v2.9) where the bolus was 
designed. The resulting bolus was exported as an STL file to 
software controlling the printer (Repetier-Host), converted to 
gcode (Slic3r) and printed on a consumer-Grade 3D printer 
(MakerGear, M2). Various rigid boluses were printed using 
polylactic acid (PLA). 
Results:  We used images acquired with the optical scanner to 
create rigid boluses for two separate regions. The first was a 
bolus for the nose which was straight forward to make and fit 
very well. The second and more complex was a bolus for the ear. 
In this case, we obtained a better fit by first filling the auditory 
canal with dental impression material. The resulting bolus had 
three parts, but was easily positioned and was a good fit. The 
field outline was printed directly onto this bolus. 
Conclusions:  The use of 3D printing technology shows great 
promise. By using the optical scanner during an initial 
consultation with the physician, one could eliminate the need for 
the patient to return for a clinical set up or mould room 
appointment. The printed bolus greatly reduces the skin-bolus 
air gap due to a personalized and tight fit to the skin surface. 
Any desired thickness of bolus material can be generated 
depending on the depth that needs to be treated and energy of 
radiation that is being used. We are not limited by the 
commercially available bolus materials, which can usually only 
be used in increments of 0.5 cm. Using this technology allows 
boluses to be made easily for complex skin surfaces. It is 
anticipated that the daily setup time on machine will be 
reduced, saving valuable treatment room time. The quality 
assurance process and dosimetric studies have been done and we 
are in the process of developing protocols for clinical 
